Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy

被引：57
作者：
Amato, Robert J. [1 ]
机构：
[1] Methodist Hosp, Res Inst, Genitourinary Oncol Program, Houston, TX 77030 USA
来源：
CLINICAL GENITOURINARY CANCER | 2007年 / 5卷 / 07期
关键词：
D O I：
10.3816/CGC.2007.n.029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Results of preclinical studies and clinical phase I/II trials suggest that the antisense oligodeoxynucleotide and DNA methyltransferase inhibitor MG98 can safely and effectively lead to reactivation of methylation silence tumor suppressor genes. It is possible that daily or continuous dosing of MG98 might be more active and less toxic than intermittent dosing. Combination of MG98 with other agents having completely different mechanisms of action seems reasonable. One clinical trial now under way is evaluating the use of MG98 in combination with interferon-a in patients with advanced renal cell carcinoma (RCC). Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest.
引用
收藏
页码：422 / 426
页数：5
相关论文
共 21 条
  • [11] Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
    Herman, JG
    Baylin, SB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) : 2042 - 2054
  • [12] KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594
  • [13] REGULATION OF DNA METHYLATION BY THE RAS SIGNALING PATHWAY
    MACLEOD, AR
    ROULEAU, J
    SZYF, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (19) : 11327 - 11337
  • [14] CpG methylation is maintained in human cancer cells lacking DNMT1
    Rhee, I
    Jair, KW
    Yen, RWC
    Lengauer, C
    Herman, JG
    Kinzler, KW
    Vogelstein, B
    Baylin, SB
    Schuebel, KE
    [J]. NATURE, 2000, 404 (6781) : 1003 - 1007
  • [15] DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
    Rhee, I
    Bachman, KE
    Park, BH
    Jair, KW
    Yen, RWC
    Schuebel, KE
    Cui, HM
    Feinberg, AP
    Lengauer, C
    Kinzler, KW
    Baylin, SB
    Vogelstein, B
    [J]. NATURE, 2002, 416 (6880) : 552 - 556
  • [16] DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells
    Robert, MF
    Morin, S
    Beaulieu, N
    Gauthier, F
    Chute, IC
    Barsalou, A
    MacLeod, AR
    [J]. NATURE GENETICS, 2003, 33 (01) : 61 - 65
  • [17] A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
    Stewart, DJ
    Donehower, RC
    Eisenhauer, EA
    Wainman, N
    Shah, AK
    Bonfils, C
    MacLeod, AR
    Besterman, JM
    Reid, GK
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (05) : 766 - 774
  • [18] DNA METHYLATION PROPERTIES - CONSEQUENCES FOR PHARMACOLOGY
    SZYF, M
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 233 - 238
  • [19] The DNA methylation machinery as a target for anticancer therapy
    Szyf, M
    [J]. PHARMACOLOGY & THERAPEUTICS, 1996, 70 (01) : 1 - 37
  • [20] Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
    Winquist, E
    Knox, J
    Ayoub, JP
    Wood, L
    Wainman, N
    Reid, GK
    Pearce, L
    Shah, A
    Eisenhauer, E
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) : 159 - 167
123